Through identifying and targeting potential biomarkers that regulate the TME, such as SEMA7A, collagen, and COX-2, we can further our understanding of contributing factors to DCIS invasion and begin to address overtreatment and anxiety in DCIS patients with safer, less toxic, interventions. The gene discussed is SEMA7A; the disease is ductal breast carcinoma in situ.